Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan-melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 7, 2012, Pages 1415-1416

  Campbell, Philip ^a   Friebe, Adam ^a   Foulstone, Paul ^a   Grigg, Andrew ^b   Hempton, Jennifer ^a   Bajel, Ashish ^b  

^a GEELONG HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; MELPHALAN; PALIFERMIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CRYOTHERAPY; DIARRHEA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LETTER; MALE; NONHODGKIN LYMPHOMA; ORAL MUCOSITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE;

ADULT; BUSULFAN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROBLAST GROWTH FACTOR 7; GASTRIC MUCOSA; HODGKIN DISEASE; HUMANS; INTESTINAL MUCOSA; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; MUCOSITIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862734237     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.653639     Document Type: Letter

References (10)

1. Grigg A, Clarke K, Szer J. Prolonged disease-free survival after autografting for chemosensitive non-bulky low grade non-Hodgkin ' s lymphoma. Leuk Lymphoma 2000;39:283-290. (Pubitemid 32162365)
2. Grigg A, Stone J, Milner A, et al. Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leuk Lymphoma 2010;51:641-649.
3. Elting L, Shih Y, Stiff P, et al. Economic impact of palifermin onthe costs of hospitalization for autologous haemopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant 2007;13:806-813. (Pubitemid 46902435)
4. Stiff P, Emmanouilides C, Bensinger W, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the haemopoietic stem-cell transplantation setting. J Clin Oncol 2006;24:5186-5193. (Pubitemid 46646481)
5. Horsley P, Bauer J, Mazkowiack R, et al. Palifermin improves severe mucositis swallowing problems, nutritional impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer 2007;15:105-109. (Pubitemid 46088321)
6. Tsirigotis P, Triantafyllou K, Girkas K, et al. Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. Bone Marrow Transplant 2008;42:337-343.
7. Svanberg A, Birgegard G, Ohrn K. Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy - a randomized controlled trial. Support Care Cancer 2007;15:1155-1161. (Pubitemid 47459869)
8. Bradstock K, Matthews J, Young G, et al. Effects of glycosylatedrecombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia 2001;15:1331-1338. (Pubitemid 32785302)
9. Dean R, Pohlman B, Sweetenham J, et al. Superior survivalafter replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with bulsulfan, cyclophosphamide and etoposide. Br J Haematol 2009;148:226-234.
10. Andersson B, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IVBuCy2) for hematologic malignancies prior to allogeneic stem cell transplan tation: a phase II study. Biol Blood Marrow Transplant 2002;8:145-154. (Pubitemid 34285073)